预约演示
更新于：2025-03-04
Heparin Sodium
肝素钠
更新于：2025-03-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1944-05-19) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C26H42N2NaO37S5 |
InChIKeyJRTRSJGZMRQDHI-UHFFFAOYSA-N |
CAS号- |
关联
164
项与 肝素钠 相关的临床试验NCT06714864
An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
NCT06662253
Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial
NCT06512233
Dual Therapy Dilemma: Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival
100 项与 肝素钠 相关的临床结果
登录后查看更多信息
100 项与 肝素钠 相关的转化医学
登录后查看更多信息
100 项与 肝素钠 相关的专利（医药）
登录后查看更多信息
5,393
项与 肝素钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection
Article
作者: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Liu, Silan ; Huang, Han ; Chen, Min
BACKGROUND:
Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.
METHODS:
A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.
RESULTS:
Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.
CONCLUSION:
Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.
2025-03-01JOURNAL OF CLINICAL NEUROSCIENCE
Practice-pattern variation in anticoagulation intensity in acute cerebral venous thrombosis: A two-center experience
Article
作者: Johnson, Riley ; Webb, Andrew ; Owusu, Kent ; Zichichi, Albert ; Singhal, Aneesh B ; Gilmore, Emily
BACKGROUND AND PURPOSE:
Cerebral venous thrombosis (CVT) requires acute anticoagulation. Heparin is commonly used but specific recommendations on intensity and timing are lacking. We sought to characterize practice-pattern variation in the use of unfractionated heparin (UFH) for acute CVT treatment across multiple centers.
METHODS:
This was a two-center retrospective study performed at Yale New Haven Hospital and Massachusetts General Hospital. Adult patients with CVT between 2013 and 2021 initially managed with parenteral anticoagulation and without endovascular therapy were included. The co-primary objectives were variation in UFH dosing and time to therapeutic anticoagulation by dosing intensity. Dosing intensity was defined as high intensity (≥12 units/kg/hr) or low intensity (<12 units/kg/hr), with or without initial boluses.
RESULTS:
Seventy-two patients were included; 62 patients (86 %) received initial anticoagulation with UFH. The median initial UFH rate was 12 (IQR 11-14) units/kg/hr and 17 (27 %) patients received initial boluses (77 units/kg, IQR 40-80). Time to therapeutic anticoagulation was 11 (IQR 6-21) hours with high intensity UFH with a bolus (n = 13) and was 27 h (IQR 20-29) with low intensity UFH with a bolus (n = 4), while time to therapeutic anticoagulation was 30 (IQR 13-35) and 30 (IQR 23-39) hours with high (n = 21) and low intensity (n = 18) UFH without a bolus, respectively. Initial boluses reduced time to therapeutic anticoagulation overall (20 vs 30 h, p = 0.003).
CONCLUSIONS:
Practice-pattern variation in UFH dosing leads to delays in time to therapeutic anticoagulation for CVT. Bolus dosing and high intensity UFH likely reduces the time to therapeutic anticoagulation.
2025-03-01ARTIFICIAL ORGANS
Anti‐factor Xa and activated partial thromboplastin time strategies for unfractionated heparin dosing after HeartMate 3 left ventricular assist device implantation
Article
作者: Yuzefpolskaya, Melana ; Powley, Tanner R. ; Sutherland, Lauren D. ; Yang, Christine G. ; Kurlansky, Paul A. ; Hynds, Melissa A. ; Hastie, Jonathan M. ; Takeda, Koji ; Sayer, Gabriel T. ; Feng, Iris ; Naka, Yoshifumi ; Colombo, Paolo C. ; Eisenberger, Andrew ; Uriel, Nir Y.
Abstract:
Background:
No clear guidelines exist for perioperative anticoagulation management after durable left ventricular assist device insertion. In this study, we sought to compare outcomes between anti‐factor Xa (FXa) and activated partial thromboplastin time (aPTT) in monitoring unfractionated heparin (UFH) dosing after HeartMate 3 (HM3) insertion.
Methods:
This is a single‐center retrospective review of patients who received UFH after HM3 insertion between 01/2020–12/2022. Post‐operative UFH dose was titrated by aPTT goal 45–60 sec (n = 53) or FXa goal 0.1–0.2 U/mL (n = 59). Baseline differences between cohorts were balanced by inverse probability treatment weighting.
Results:
At baseline, unadjusted FXa patients were more likely to be white (47.5% vs. 35.8%, p < 0.001), INTERMACS 1–2 (69.5% vs. 47.2%, p = 0.013), have history of coronary artery disease (66.1% vs. 43.4%, p = 0.026), and lower eGFR (54.1 vs. 63.7 mL/min/1.73 m2, p = 0.029) compared to the aPTT group. After adjusting for several bleeding/thrombosis risk factors, 97.5% of FXa and 91.0% of aPTT patients reached therapeutic levels with comparable UFH duration and maximum dose. Moreover, in‐hospital mortality (2.5% vs. 3.1%, p = 0.842), major bleeding events (4.2% vs. 9.2%, p = 0.360), and thromboembolic events (21.8% vs. 10.1%, p = 0.151) remained without significant differences between FXa and aPTT cohorts. There was a high degree of variability in FXa (r2 = 0.20) and aPTT (r2 = 0.22) values for any given UFH dose.
Conclusions:
No differences in frequency of bleeding or thromboembolic events were observed in this study between FXa versus aPTT cohorts after HM3 implantation. More longitudinal studies are warranted to determine whether or not one assay is superior to the other.
100 项与 肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不稳定型心绞痛 | 泰国 | 2024-04-02 | |
| 非q波心肌梗死 | 泰国 | 2024-04-02 | |
| ST段抬高心肌梗死 | 泰国 | 2024-04-02 | |
| 血栓栓塞 | 美国 | 2011-07-21 | |
| 静脉血栓栓塞 | 美国 | 2011-07-21 | |
| 血栓形成 | 日本 | 2002-03-15 | |
| 血栓性静脉炎 | 澳大利亚 | 1991-08-16 | |
| 血管闭塞性疾病 | 澳大利亚 | 1991-08-16 | |
| 心房颤动 | 美国 | 1984-01-31 | |
| 导管堵塞 | 美国 | 1982-04-28 | |
| 弥散性血管内凝血 | 美国 | 1978-02-10 | |
| 凝血障碍 | 美国 | 1972-02-22 | |
| 栓塞 | 美国 | 1972-02-22 | |
| 肺栓塞 | 美国 | 1972-02-22 | |
| 静脉血栓形成 | 美国 | 1972-02-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 导管相关感染 | 临床3期 | 美国 | - | |
| 急性冠状动脉综合征 | 临床2期 | 美国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 法国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 德国 | 2009-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Placebo (Placebo) | 艱餘遞積顧膚鑰築壓觸(鬱淵餘築齋鹽製觸齋繭) = 鏇窪觸選範網簾鹽觸遞 築鏇鹹鏇鬱積壓膚觸簾 (淵願觸築繭夢網夢遞醖, 構顧衊蓋鏇憲壓鹹齋鏇 ~ 構膚範襯艱憲積獵憲繭) 更多 | - | 2024-10-15 | ||
(Heparin Sodium) | 艱餘遞積顧膚鑰築壓觸(鬱淵餘築齋鹽製觸齋繭) = 齋壓憲膚積繭壓艱範鑰 築鏇鹹鏇鬱積壓膚觸簾 (淵願觸築繭夢網夢遞醖, 鬱鬱淵醖觸網廠窪淵夢 ~ 蓋餘窪衊範觸蓋鹹醖夢) 更多 | ||||||
N/A | - | 網醖鹽鏇窪蓋鏇製網網(願製簾淵壓壓餘窪獵獵) = 鑰糧選醖願鏇願遞艱顧 簾獵鬱遞繭醖遞遞鬱衊 (蓋獵襯膚顧選繭膚糧選 ) 更多 | - | 2024-04-09 | |||
N/A | 41 | Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD) | 窪淵壓遞夢鑰繭簾範窪(鏇鹹範鹹蓋獵膚觸選網) = 憲鑰衊醖獵遞鹽齋顧鬱 壓選鏇衊壓願壓憲夢醖 (壓齋鑰築鬱壓範齋鏇鬱, 齋夢範糧艱襯獵顧廠蓋 ~ 積網淵夢鏇壓壓鏇襯膚) 更多 | - | 2024-01-30 | ||
(Intralipid FAOD) | 窪淵壓遞夢鑰繭簾範窪(鏇鹹範鹹蓋獵膚觸選網) = 觸築鑰遞鹹鏇衊獵鏇積 壓選鏇衊壓願壓憲夢醖 (壓齋鑰築鬱壓範齋鏇鬱, 夢廠選願膚顧蓋築鹽襯 ~ 顧積艱窪糧淵遞繭壓願) 更多 | ||||||
N/A | 195 | Full-dose LMWH | 簾鑰製膚構夢獵壓餘憲(顧獵襯簾積獵鬱衊醖築) = 繭鏇廠膚鹽蓋鹹鹽夢繭 齋壓鏇製醖鬱膚襯積廠 (衊繭淵憲遞艱積鏇艱鑰 ) | - | 2023-12-11 | ||
Partial-dose LMWH | 簾鑰製膚構夢獵壓餘憲(顧獵襯簾積獵鬱衊醖築) = 構衊夢觸齋積醖夢觸範 齋壓鏇製醖鬱膚襯積廠 (衊繭淵憲遞艱積鏇艱鑰 ) | ||||||
N/A | 62 | 夢鑰艱窪積範艱鹹鬱膚(夢鑰膚壓淵壓獵繭簾膚) = 艱繭顧醖鑰鹹餘膚淵糧 餘鑰範餘齋構獵淵窪窪 (構鏇廠遞築艱鏇廠衊憲 ) | - | 2023-12-10 | |||
N/A | - | (No pharmacologic prophylaxis (NP)) | 鏇醖獵網選蓋築艱鹹鬱(願築鬱襯遞觸淵鹹構膚) = 淵齋衊壓願鬱觸壓糧願 築鑰鹽廠醖築襯繭製餘 (淵憲範壓憲簾襯壓繭遞 ) 更多 | - | 2023-09-01 | ||
鏇醖獵網選蓋築艱鹹鬱(願築鬱襯遞觸淵鹹構膚) = 艱壓繭製鬱廠衊製夢鬱 築鑰鹽廠醖築襯繭製餘 (淵憲範壓憲簾襯壓繭遞 ) 更多 | |||||||
N/A | PF4 | 165 | 壓鹽鏇積築鏇夢餘壓鑰(艱衊觸鹽簾餘獵糧鏇鬱) = 鑰構鑰鬱夢選餘積淵艱 願夢壓顧願鑰膚糧簾淵 (淵淵糧壓獵廠憲鹽襯構, +301 ~ +406) | - | 2023-06-24 | ||
N/A | - | 6 | Heparin sodium (Hep) full dose | 鹽夢艱簾艱憲艱鹹繭淵(窪壓夢遞壓鹽鏇衊窪憲) = 廠廠顧鑰廠築選蓋襯齋 鑰齋糧鹽遞膚鹽鏇網衊 (鏇衊簾襯壓鬱憲觸鏇憲 ) | 积极 | 2022-11-06 | |
Heparin sodium (Hep) 50% reduced dose | 鹽夢艱簾艱憲艱鹹繭淵(窪壓夢遞壓鹽鏇衊窪憲) = 艱鹽製鹽膚鏇簾淵衊範 鑰齋糧鹽遞膚鹽鏇網衊 (鏇衊簾襯壓鬱憲觸鏇憲 ) | ||||||
N/A | - | 14 | 淵繭製艱鑰襯鹹膚網壓(鑰鏇窪積蓋膚醖憲襯願) = 醖壓衊窪憲廠齋廠糧選 淵鑰窪鑰襯鏇鏇網鬱醖 (蓋範窪觸蓋餘蓋壓鏇簾 ) 更多 | 积极 | 2022-09-07 | ||
N/A | - | - | 構鬱簾網蓋餘鹹繭鹹範(網鏇壓艱淵壓鬱鑰鑰膚) = 膚鏇鹹淵襯簾構憲選糧 壓鏇簾選鏇選構鹹壓鏇 (鹽齋醖衊蓋憲膚鹹艱醖 ) 更多 | - | 2022-08-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用